DK1146896T3 - Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger - Google Patents

Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger

Info

Publication number: DK1146896T3
Authority: DK; Denmark
Prior art keywords: human insulin; modified; acylated; formulations; formulations containing
Prior art date: 1999-01-26

Application number

DK00904496T

Other languages

English (en)

Inventor

Kingman Ng

Shun Li

Eric Alan Watts

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-26

Filing date

2000-01-26

Publication date

2002-09-02

2000-01-26 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2002-09-02 Application granted granted Critical

2002-09-02 Publication of DK1146896T3 publication Critical patent/DK1146896T3/da

Links

238000009472 formulation Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 4
239000007864 aqueous solution Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
101500025353 Homo sapiens Insulin A chain Proteins 0.000 abstract 1
101500025354 Homo sapiens Insulin B chain Proteins 0.000 abstract 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
125000005313 fatty acid group Chemical group 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Inorganic Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

DK00904496T 1999-01-26 2000-01-26 Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger DK1146896T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11729199P	1999-01-26	1999-01-26
PCT/US2000/001627 WO2000043034A2 (en)	1999-01-26	2000-01-26	Monodisperse hexameric acylated insulin analog formulations

Publications (1)

Publication Number	Publication Date
DK1146896T3 true DK1146896T3 (da)	2002-09-02

Family

ID=22372048

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00904496T DK1146896T3 (da)	1999-01-26	2000-01-26	Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger

Country Status (9)

Country	Link
EP (1)	EP1146896B1 (da)
JP (1)	JP2002535287A (da)
AT (1)	ATE220917T1 (da)
AU (1)	AU2624400A (da)
DE (1)	DE60000288T2 (da)
DK (1)	DK1146896T3 (da)
ES (1)	ES2180511T3 (da)
PT (1)	PT1146896E (da)
WO (1)	WO2000043034A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7169889B1 (en)	1999-06-19	2007-01-30	Biocon Limited	Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7060675B2 (en)	2001-02-15	2006-06-13	Nobex Corporation	Methods of treating diabetes mellitus
US6835802B2 (en)	2001-06-04	2004-12-28	Nobex Corporation	Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
EP1506003A1 (en) *	2002-05-07	2005-02-16	Novo Nordisk A/S	Soluble formulations comprising insulin aspart and insulin detemir
JP5599543B2 (ja)	2002-05-07	2014-10-01	ノヴォノルディスクアー／エス	単量体インスリン及びアシル化インスリンを含む可溶性製剤
AU2003297583B2 (en)	2002-11-26	2010-01-14	Biocon, Ltd	Modified naturetic compounds, conjugates, and uses thereof
US7648962B2 (en)	2002-11-26	2010-01-19	Biocon Limited	Natriuretic compounds, conjugates, and uses thereof
BRPI0513508B1 (pt) *	2004-07-19	2021-06-01	Biocon Limited	Conjugados de insulina-oligômero, formulações e usos desses
JP4808785B2 (ja)	2005-12-28	2011-11-02	ノボ・ノルデイスク・エー／エス	インスリン組成物および組成物の製造方法
ES2542146T3 (es)	2006-07-31	2015-07-31	Novo Nordisk A/S	Insulinas extendidas PEGiladas.
DK2074141T3 (da)	2006-09-22	2016-11-28	Novo Nordisk As	Proteaseresistente insulinanaloger.
US9387176B2 (en)	2007-04-30	2016-07-12	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9034818B2 (en)	2007-06-13	2015-05-19	Novo Nordisk A/S	Pharmaceutical formulations comprising an insulin derivative
WO2009112583A2 (en)	2008-03-14	2009-09-17	Novo Nordisk A/S	Protease-stabilized insulin analogues
CN102037008B (zh)	2008-03-18	2016-08-31	诺沃-诺迪斯克有限公司	蛋白酶稳定化的、酰化胰岛素类似物
AU2009309623B9 (en)	2008-10-30	2014-10-02	Novo Nordisk A/S	Treating diabetes melitus using insulin injections with less than daily injection frequency
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US9481721B2 (en)	2012-04-11	2016-11-01	Novo Nordisk A/S	Insulin formulations
EP2919804B1 (fr)	2012-11-13	2018-01-31	Adocia	Formulation à action rapide d'insuline comprenant un composé anionique substitué
JP2016519127A (ja)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	新規投与レジメン
AU2014333979B2 (en)	2013-10-07	2018-02-15	Novo Nordisk A/S	Novel derivative of an insulin analogue
AR102869A1 (es)	2014-12-16	2017-03-29	Lilly Co Eli	Composiciones de insulina de rápida acción
JO3749B1 (ar)	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
TWI700091B (zh) *	2016-12-16	2020-08-01	丹麥商諾佛儂迪克股份有限公司	含胰島素醫藥組成物
KR20190140048A (ko)	2017-06-01	2019-12-18	일라이 릴리 앤드 캄파니	신속-작용 인슐린 조성물
CN111032685A (zh)	2017-08-17	2020-04-17	诺沃挪第克公司	新型酰化胰岛素类似物及其用途
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
US20220289811A1 (en) *	2019-08-16	2022-09-15	Lamark Biotech Pvt Limited	A formulation of insulin based on crystal-seeding in hydrogels and method thereof
WO2025061146A1 (zh) *	2023-09-20	2025-03-27	上海迈晋生物医药科技有限公司	一种人胰岛素类似物融合蛋白的药物组合物及其医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE208208T1 (de) *	1996-06-20	2001-11-15	Novo Nordisk As	Halogenid-enthaltende insulinzubereitungen
ES2242270T3 (es) *	1997-02-07	2005-11-01	Novo Nordisk A/S	Cristalizacion de proteinas.
EP1044016B1 (en) *	1998-01-09	2005-03-16	Novo Nordisk A/S	Stabilised insulin compositions

2000
- 2000-01-26 ES ES00904496T patent/ES2180511T3/es not_active Expired - Lifetime
- 2000-01-26 WO PCT/US2000/001627 patent/WO2000043034A2/en not_active Ceased
- 2000-01-26 PT PT00904496T patent/PT1146896E/pt unknown
- 2000-01-26 DK DK00904496T patent/DK1146896T3/da active
- 2000-01-26 EP EP00904496A patent/EP1146896B1/en not_active Expired - Lifetime
- 2000-01-26 JP JP2000594487A patent/JP2002535287A/ja not_active Withdrawn
- 2000-01-26 AU AU26244/00A patent/AU2624400A/en not_active Abandoned
- 2000-01-26 AT AT00904496T patent/ATE220917T1/de not_active IP Right Cessation
- 2000-01-26 DE DE60000288T patent/DE60000288T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2180511T3 (es)	2003-02-16
AU2624400A (en)	2000-08-07
EP1146896B1 (en)	2002-07-24
DE60000288T2 (de)	2003-01-16
ATE220917T1 (de)	2002-08-15
DE60000288D1 (de)	2002-08-29
WO2000043034A2 (en)	2000-07-27
EP1146896A2 (en)	2001-10-24
WO2000043034A3 (en)	2000-12-28
JP2002535287A (ja)	2002-10-22
PT1146896E (pt)	2002-10-31

Publication	Publication Date	Title
DK1146896T3 (da)	2002-09-02	Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger
WO2002043750A3 (en)	2002-10-31	Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
HUP0100243A2 (hu)	2001-08-28	Inzulint és/vagy inzulin-analógokat és azok származékait tartalmazó oldhatatlan készítmények, eljárás azok előállítására és alkalmazásuk a vércukor szintjének szabályozására
EP1808438A3 (en)	2008-12-24	Purification and stabilization of peptide and proteins in pharmaceutical agents
DE58901401D1 (de)	1992-06-17	Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
GB9316895D0 (en)	1993-09-29	Hepatoselective insulin analogues
MY121291A (en)	2006-01-28	Fracture healing using pthrp analogs
EA200000748A1 (ru)	2000-12-25	Способ введения мономерных аналогов инсулина
EP2308963A3 (en)	2011-09-21	System for processing lipoaspirate cells
WO2007130113A3 (en)	2008-10-30	Parathyroid hormone analogues and methods of use
PE19496A1 (es)	1996-06-01	Formulacion de analogo de insulina humana
AU563642B2 (en)	1987-07-16	Oral antidiabetic composition
TW200631592A (en)	2006-09-16	Soluble, stable insulin-containing formulations
NO20005625L (no)	2001-01-05	Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN)
WO1996024370B1 (en)	1996-09-19	Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
BR9811755A (pt)	2000-08-29	Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
CA2522146A1 (en)	2005-10-13	Uptake of macromolecules
TW286320B (da)	1996-09-21
IL148797A (en)	2010-12-30	Metal-binding compounds and uses thereof
BR9006746A (pt)	1991-08-06	Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
PT97878A (pt)	1992-12-31	Processo para a preparacao de uma composicao farmaceutica para uso oftalmico contendo hexetidina ou seus derivados ou sais
MX9704388A (es)	1998-07-31	Incremento de la concentracion de creatina y glicogeno en musculos.
TH12479B (th)	2002-04-17	สูตรผสมของสารคล้ายอินซูลิน